Pharmaxis to apply for Australian marketing approval of respiratory drug
Pharmaxis will submit its marketing authorization application following the conclusion of the ongoing safety component of the Phase III trial – an optional 12 month extension to determine
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.